Search terms
Results 1 - 6 of 6 - ordered by :

Prof. Zannad points out that, “Rivaroxaban is approved at higher doses to treat conditions such as atrial fibrillation (AF) and venous thromboembolism, but in COMMANDER HF, patients were ...

Date : 28/08/2018

Dr. Kelley Branch Among patients with stable coronary artery disease (CAD) and/or peripheral artery disease (PAD), those with heart failure are at a higher risk of major adverse cardiovascular events ...

Date : 29/05/2018

Formerly considered diuretics, mineralocorticoid receptor antagonists (MRAs) “are still underused in routine clinical practice, but our data may hopefully contribute to expanded use of these ...

Date : 28/08/2017

Beta blockers, aldosterone antagonists and in particular ACE-inhibitors have been the gold standard for the treatment of patients suffering from heart failure due to reduced ejection fraction for the ...

Date : 28/01/2015

Frailty increases risk of death or repeat heart attack in elderly MI patients by three-fold Frailty increases the risk of death or repeat heart attack in elderly MI patients by three-fold, according ...

Date : 30/08/2014

The primary outcome measure was time to first event for the composite endpoint of cardiovascular death, resuscitated death, myocardial infarction, stroke, unplanned hospitalisation for heart failure, ...

Date : 26/08/2012